MAPLE GROVE, Minn., Aug. 25, 2016 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith) announced that it has entered into an exclusive agreement with an emerging pharmaceutical company to market and distribute a generic central nervous system (CNS) product with U.S. sales of more than $200 million for the 12 months ending June 2016, according to IMS Health. This collaboration is part of Upsher-Smith's company-wide effort to grow its generics pipeline and to expand its strategic relationships within the pharmaceutical industry.
Under the terms of the agreement, the partner will develop, manufacture and supply the product exclusively for Upsher-Smith, which will market and distribute the product under its own label in the United States. Financial terms related to the deal have not been disclosed.
"Upsher-Smith has long been recognized within the pharmaceutical industry as a trusted name in the generics marketplace," said Rusty Field, President, Upsher-Smith. "This new agreement demonstrates the company's commitment to expanding its portfolio of high-quality, high-value generic products for patients."
Upsher-Smith Laboratories, Inc., founded in 1919, is a growing, fully integrated pharmaceutical company dedicated to its mission of delivering high-value, high-quality therapies and solutions which measurably improve individuals' lives. As a family-owned pharmaceutical company, we are able to adapt and thrive in a dynamic healthcare environment. Our world is constantly evolving, and we are continually adapting to the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations. Where there is a need, we will work to deliver solutions that simplify access to treatment, deliver better health outcomes, and enhance life. For more information, visit www.upsher-smith.com.
SOURCE Upsher-Smith Laboratories, Inc.